CEFAZOLIN SODIUM (cefazolin) by Novartis is clinical pharmacology after intramuscular administration of cefazolin for injection to normal volunteers, the mean serum concentrations were 37 mcg/ml at 1 hour and 3 mcg/ml at 8 hours following a 500-mg dose, and 64 mcg/ml at 1 hour and 7 mcg/ml at 8 hours following a 1-gram dose. Approved for the treatment of the following serious infections due to susceptible organisms: respiratory tract infections: due to s, development of drug-resistant bacteria, maintain the effectiveness of cefazolin for injection and 5 more indications. First approved in 2018.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY After intramuscular administration of Cefazolin for Injection to normal volunteers, the mean serum concentrations were 37 mcg/mL at 1 hour and 3 mcg/mL at 8 hours following a 500-mg dose, and 64 mcg/mL at 1 hour and 7 mcg/mL at 8 hours following a 1-gram dose. Studies have…
Worked on CEFAZOLIN SODIUM at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults
Cefazolin PK Study 3g vs 2g
Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects
Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients
An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo